Silence Therapeutics plc Stock London S.E.
Stocks
SLN
GB00B9GTXM62
Biotechnology & Medical Research
OTC Markets Traded
| Market Cap | 247M 327M 285M 264M 464M 30.87B 467M 3.13B 1.21B 15.19B 1.23B 1.2B 52.76B | P/E 2026 * |
-11.1x | P/E 2027 * | -11x |
|---|---|---|---|---|---|
| Enterprise Value | 94.6M 125M 109M 101M 177M 11.81B 178M 1.2B 465M 5.81B 470M 460M 20.18B | EV / Sales 2026 * |
33.1x | EV / Sales 2027 * | -11.4x |
| Free-Float |
69.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| 1 day | -0.93% |
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 2025-12-13 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 2022-02-20 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 2018-06-20 |
Iain Ross
CHM | Chairman | 72 | 2019-11-30 |
Rhonda Hellums
BRD | Director/Board Member | 54 | 2025-12-17 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.93% | -2.73% | - | - | 327M | |
| +1.44% | +1.71% | -10.98% | -6.19% | 43.13B | |
| +3.31% | +5.93% | +310.97% | +534.70% | 34.65B | |
| +2.84% | +2.14% | +9.34% | +41.02% | 30.03B | |
| -1.70% | -7.54% | +8.43% | -21.94% | 28B | |
| -1.90% | -1.56% | +10.24% | +21.21% | 24.45B | |
| -0.14% | +5.86% | - | - | 14.34B | |
| +0.68% | -1.53% | +48.76% | +104.27% | 13.14B | |
| -0.57% | -2.43% | +5.08% | +4.79% | 12.53B | |
| -0.26% | +1.15% | +98.13% | +80.47% | 12.25B | |
| Average | +0.28% | +0.73% | +60.00% | +94.79% | 23.61B | |
| Weighted average by Cap. | +0.77% | +1.27% | +65.47% | +110.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.86M 3.78M 3.3M 3.06M 5.37M 357M 5.4M 36.25M 14.05M 176M 14.21M 13.9M 610M | 4.13M 5.46M 4.76M 4.41M 7.74M 515M 7.79M 52.32M 20.28M 254M 20.5M 20.06M 881M |
| Net income | -49.12M -64.97M -56.65M -52.47M -92.11M -6.13B -92.67M -622M -241M -3.02B -244M -239M -10.48B | -80.11M -106M -92.39M -85.57M -150M -10B -151M -1.02B -393M -4.92B -398M -389M -17.09B |
| Net Debt | -153M -202M -176M -163M -286M -19.06B -288M -1.94B -750M -9.38B -758M -742M -32.58B | -294M -389M -339M -314M -552M -36.74B -555M -3.73B -1.45B -18.08B -1.46B -1.43B -62.79B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
